^(99m)Tc-MDP治疗骨质疏松症疗效评价

Efficacy of ^(99m)Tc-MDP in treatment of osteoporosis

目的评价稳定性核素99m锝-亚甲基二膦酸盐(99mTc-MDP)治疗骨质疏松症的效果。方法93例骨质疏松症患者随机分为治疗组58例与对照组35例。治疗组采用99mTc-MDP注射治疗:99mTc10ml及MDP10ml加入0.9%氯化钠注射液50ml中静脉滴注,1次/d,10～15d为1个疗程;对照组常规口服钙剂及维生素D制剂。分别观察2组治疗前及治疗3、6、12个月时血中骨钙素(BGP)、骨特异性碱性磷酸酶(BALP)及骨密度(BMD)的变化。结果治疗组治疗3个月后BMD、BGP值出现增高,在6个月时明显增高(P均<0.05);BALP值逐渐降低,与治疗前比较差异有统计学意义(P均<0.05);对照组治疗前后3项指标均无变化。治疗6、12个月时2组各指标的比较差异有统计学意义(P均<0.05)。结论99mTc-MDP治疗能较快地增加机体BMD,降低骨吸收,增加骨强度,对骨质疏松症有较好疗效。

Objective To evaluate the efficacy of stable nuclide 99mTc medronate methylene diphosphonate （99mTc-MDP） in treatment of osteoporosis. Methods Ninety-three patients with osteoporosis were randomly divided into treatment group （ n = 58） and control group （ n = 35）. Patients in treatment group received 99mTe-MDP （99mTc 10 ml and MDP 10 ml dissolved in 0. 9% NaCI solution 50 ml intravenous infusion once a day, 10 - 15 days as a course of treatment）. Patients in control group were administered calcium and vitamin D at routine dose. The changes of bone gin protein （BGP） , bone alkaline phosphatase （BALP） and bone mineral density （BMD） of all patients were observed before and ＇after 3,6 and 12 months of administration. Results BMD and BGP increased,while BALP decreased 6 months and 12 months after treatment （ all P 〈 0.05 ）. No obvious changes of BMD, BGP and BALP were observed in control group before and after administration. Compared to the control group, BMD, BGP and BALP in treatment group had significant differences 6 and 12 months after treatment （ all P 〈 0. 05 ）. Conclusions 99mTc-MDP can increase BMD and bone strength, decrease bone resorption, therefore it could be presented as an efficacious drug in treatment of osteoporosis.